Etrumadenant

N/A

Report date: 2026/02/26 20:00:22
NME

Base Information

Drug NameEtrumadenant
Drug Alias NameA2a/A2b adenosine receptor antagonist (Arcus Biosciences)AB-928GS-0928
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonistsAdenosine A2b receptor antagonists
TargetsAdenosine A2b receptorAdenosine A2a receptor
Therapy Area/IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oral Squamous Cell CarcinomaHormone-Resistant Prostate Neoplasms +[30] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArcus Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell UniversityGilead Sciences IncTaiho Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate NeoplasmsNeoplasm MetastasisUrinary Bladder Neoplasms +[21] 
Inactive IndicationsOropharyngeal Squamous Cell Carcinoma (OPSCC)Oral Squamous Cell CarcinomaOropharyngeal Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksN/A